Guotai Bio-medicine ETF (512290) rose over 1%, with the focus on innovative drugs going overseas and value realization becoming the core highlight

腾讯新闻 - 财经
2026.04.14 10:53
portai
I'm LongbridgeAI, I can summarize articles.

Guotai CSI Bio-medicine ETF (512290) rose over 1% on April 14, with the focus on innovative drugs going overseas and value realization becoming the market highlight. Xiangcai Securities pointed out that the 2025 global pharmaceutical sales TOP 100 list shows that the industry landscape is undergoing profound changes, with market growth momentum shifting from tumor immunity to chronic diseases such as metabolic disorders, particularly the rise of GLP-1 drugs. Technological iteration has spawned new growth poles, and innovative therapies have become the new engine of growth. This ETF tracks the CSI Bio-medicine Index, reflecting the overall performance of listed companies in the biopharmaceutical sector. Risk warning: Individual stock analysis does not constitute investment advice; investment should be approached with caution

Source: 腾讯新闻 - 财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer